Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bitdeer Technologies Group (BTDR) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

Bitdeer Technologies GroupTrade
State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

Bitdeer Technologies Group vs State Street SPDR S&P Biotech ETF — how do they compare? Bitdeer Technologies Group trades at $9.18 (market cap $2.36B), while State Street SPDR S&P Biotech ETF trades at $159.2. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Bitdeer Technologies Group nearer its low. Which is the better fit depends on your goals.

BTDRXBI
Market Cap
$2.36B
Sector
TechnologyBroad Market / Factor
52-Week High
$25.90$164.28
52-Week Low
$7.28$86.92
Enterprise Value
$3.85B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bitdeer Technologies Group

BTDR trades at $9.30, up 6.96% today, but faces bearish technical signals with 13 of 13 moving averages signaling sell. The company reported four consecutive quarterly earnings misses, with Q2 2026 loss of $0.37 per share missing expectations. Despite negative profitability metrics (-28.14% net margin), analyst consensus remains strongly bullish with 82% buy ratings and $22.43 price target. Recent $4.7 billion AI data center deal provides long-term revenue visibility amid Bitcoin mining challenges.

The stock presents high-risk opportunity with significant analyst upside potential but faces execution risks in transitioning from Bitcoin dependency to AI infrastructure. Near-term pressure from negative cash flow and margin compression contrasts with long-term AI contract value. Investors must weigh strong institutional support against persistent profitability challenges and crypto market volatility.

State Street SPDR S&P Biotech ETF

XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.

Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bitdeer Technologies Group

Bitdeer is a world-leading technology company for blockchain and high-performance computing. It provides comprehensive digital asset mining solutions, including cloud mining, hosting, and data center management.

Read more on BTDR

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.

Read more on XBI